New drugs in non-small cell lung cancer. An overview

Lung Cancer. 1995 Apr:12 Suppl 1:S155-62. doi: 10.1016/0169-5002(95)00431-y.

Abstract

Chemotherapy is rather ineffective in non-small cell lung cancer. However, in the last few years, a number of new anticancer agents have been developed which have definite activity in this disease. Among them are the taxanes and CPT-11, drugs with novel mechanisms of action, new antimetabolites (edatrexate and gemcitabine), and a new vinca alkaloid (vinorelbine). Furthermore, in the near future, the better understanding of lung cancer biology will help in devising new treatment strategies.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Docetaxel
  • Drug Design
  • Humans
  • Lung Neoplasms / drug therapy*
  • Paclitaxel / analogs & derivatives
  • Paclitaxel / therapeutic use
  • Taxoids*
  • Topoisomerase I Inhibitors
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use
  • Vinorelbine

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Antineoplastic Agents, Phytogenic
  • Taxoids
  • Topoisomerase I Inhibitors
  • Docetaxel
  • Vinblastine
  • Paclitaxel
  • Vinorelbine